• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 21, 2020

View Archived Issues
FDA approved road sign

Angle of ketorolac attack yakked as Baudax hails Anjeso pesos

During a conference call with investors, Baudax Bio Inc. CEO Gerri Henwood let out an exuberant “woohoo!” to celebrate the FDA’s approval – after two turndowns and much haggling over data – of Anjeso (meloxicam) for moderate to severe pain. Echoing her sentiment was Piper Sandler analyst David Amsellem. “It’s nice to see the pain division finally get this one right,” he said. Read More
Coronavirus-travel

Opportunity to control epidemic narrowing, as epidemiology gaps frustrate researchers

LONDON – Six weeks on from the initial alert, “the window of opportunity” to control the COVID-19 epidemic is “narrowing,” according to the latest assessment from World Health Organization (WHO) Director General Tedros Adhanom Ghebreyesus. Read More
Shanghai-stock-market

Bio-Thera launches $241M pre-revenue IPO on Shanghai’s STAR; shares up 83% on debut

BEIJING – Chinese biosimilar maker Bio-Thera Solutions Ltd., of Guangzhou, on Feb. 21 launched a pre-revenue listing on Shanghai’s STAR market, a Nasdaq-style tech board, to reap $241 million at a valuation of almost $2 billion. Its share price soared more than 83% during its first trading day. Read More

Shock away? Adrenomed’s adrecizumab hits phase II endpoint in septic shock

DUBLIN – Adrenomed AG disclosed Feb. 21 that its first-in-class antibody, adrecizumab, hit the primary safety and tolerability endpoint of a phase II trial in septic shock. Read More
Hemophilia-test-tube-dna

Biomarin’s BLA for Valrox gene therapy for hemophilia A accepted by FDA

Valrox (valoctocogene roxaparvovec) from San Rafael Calif-based Biomarin Pharmaceutical Inc. moved one step closer to entering the U.S. market, with the company reporting that that the FDA had accepted for priority review the BLA for its investigational AAV5 gene therapy for adults with hemophilia A. Read More
Rare diseases

Rare disease specialist Canbridge closes $98 million series D, eyes IPO next

HONG KONG – Beijing-headquartered Canbridge Pharmaceuticals Inc. has completed a $98 million series D financing round to target rare genetic diseases in China, and is considering an IPO after several rounds of financing to further pursue its goal. Read More

Digital strategies key for Indian pharma

HYDERABAD, India – To continue expanding their footprint and capabilities beyond simple generics to biosimilars and new chemical entities, Indian pharmaceutical companies will have to improve their quality controls, compliance capabilities and, just as importantly, adopt more effective digital strategies. Read More

Esperion wins FDA approval for new cholesterol-lowering drug

Less than a month after landing a positive opinion from the EMA's CHMP, Esperion Therapeutics Inc. has won FDA approval for bempedoic acid as an adjunct to diet and maximally tolerated statin therapy. Read More
Bench Press 2-21

Bench Press for Feb. 21, 2020

BioWorld looks at translational medicine, including: Noncoding RNA protects blood vessel walls; PD-1 blockade interferes with opioid analgesia; T-cell population is biomarker for beta cell function; Glutaminase 1 is NASH target; Oligodendrocyte-neural connections not just about myelin; Sharper look yields new potential kinase target in ovarian cancer; Structural insights could enable specific activation of GPCRs; Autophagy activation may prevent metastasis; AI finds structurally unique antibiotics. Read More

Appointments and advancements for Feb. 21, 2020

New hires and promotions in the biopharma industry, including: Kallyope, Predictive Oncology, Turning Point, Xbrane. Read More

Financings for Feb. 21, 2020

Biopharmas raising money in public or private financings, including: Acerus, Adamis, Agile, Akari, Algernon, Avadel, Briacell, Eyepoint, Vaxil, Xeris. Read More

In the clinic for Feb. 21, 2020

Clinical updates, including trial initiations, enrollment status and data readouts and publications: AB Science, Actinium, Adrenomed, Ampio, Cytodyn, Genfit, Harbour, Intra-Cellular, Nono, Transgene. Read More

Other news to note for Feb. 21, 2020

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aradigm, Arch, Beijing Innocare, Cyclica, Erytech, Genetron, Grifols. Read More

Regulatory actions for Feb. 21, 2020

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Baudax, Biomarin, BMS, DBV. Read More

Regulatory front for Feb. 21, 2020

The latest global regulatory news, changes and updates affecting biopharma, including: Ferring Pharmaceuticals. Read More

Biopharma money raised: Jan. 1-Feb. 20, 2020

Year-to-date money raised in public, private and other financings of biopharma companies. Read More

Money raised by biopharma: 2020 vs. 2019

Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019. Read More

Biggest gainers and losers for the week of Feb. 17-21, 2020

The top 10 biopharma stock gainers and losers for the week. Read More
Acquisition-fish.png

Completed biopharmaceutical mergers & acquisitions: January 2020

Completed biopharma M&As, including: Achillion, Alexion, Altavant Sciences, Artara, Aspen Global, Astellas, Audentes, Carriergene, Novartis, Nuprobe Global, Onspira, Proteon, Synthorx, The Medicines Co. Read More

Biopharmaceutical collaborations: January 2020

Biopharma licensings, joint ventures and collaborations, including: 4SC, Abbvie, Amgen, Aska, Astellas, Astrazeneca, Bayer, Biogen, Biomed X, Boehringer, Chiesi Farmaceutici, Clinigen, Curis, Cyclica, Daewoong, Daiichi Sankyo, Evotec, Gilead, Hikma, Innovent, Inovio, Ionis, Iovance, Janssen, Mediwound, Merck & Co., Merck KGaA, Mundipharma, Nestle, Novartis, Novo Nordisk, Pfizer, Pharmamar, Phasebio, Probiogen, Roche, Schrodinger, Syndivia, Takeda. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe